European Heart Journal

دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه

ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
~~قیمت : 3,800,000 تومان~~
قیمت ویژه : 1,900,000تومان

سفارش

Challenges of antithrombotic treatment in high-risk populations and a fond farewell to CKMB

Filippo Crea

doi : 10.1093/eurheartj/ehab345

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2221–2224

خرید پکیج و مشاهده آنلاین مقاله

Computational modelling to reduce outcome variability in tissue-engineered heart valves

Valery L Visser, Polina Zaytseva, Sarah E Motta, Sandra Loerakker, Simon P Hoerstrup, Maximilian Y Emmert

doi : 10.1093/eurheartj/ehab034

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2225–2229

خرید پکیج و مشاهده آنلاین مقاله

Editorial mini team Diabetes and Metabolic Disease

doi : 10.1093/eurheartj/ehab290

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Page 2230

خرید پکیج و مشاهده آنلاین مقاله

At the Heart of Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain

Isaac Pascual, MD, PhD, FESC, Pablo Avanzas, MD, PhD, FESC, César Mor?s, MD PhD FESC

doi : 10.1093/eurheartj/ehaa1039

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2231–2232

خرید پکیج و مشاهده آنلاین مقاله

Vulnerable non-culprit coronary plaques: are they worth treating?

Massimo Volpe, Carlo Patrono

doi : 10.1093/eurheartj/ehab232

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2233–2234

خرید پکیج و مشاهده آنلاین مقاله

Antithrombotic therapy in diabetes: which, when, and for how long?

Ramzi A Ajjan, Noppadol Kietsiriroje, Lina Badimon, Gemma Vilahur, Diana A Gorog, Dominick J Angiolillo, David A Russell, Bianca Rocca, Robert F Storey

doi : 10.1093/eurheartj/ehab128

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2235–2259

Cardiovascular disease remains the main cause of mortality in individuals with diabetes mellitus (DM) and also results in significant morbidity. Premature and more aggressive atherosclerotic disease, coupled with an enhanced thrombotic environment, contributes to the high vascular risk in individuals with DM. This prothrombotic milieu is due to increased platelet activity together with impaired fibrinolysis secondary to quantitative and qualitative changes in coagulation factors. However, management strategies to reduce thrombosis risk remain largely similar in individuals with and without DM. The current review covers the latest in the field of antithrombotic management in DM. The role of primary vascular prevention is discussed together with options for secondary prevention following an ischaemic event in different clinical scenarios including coronary, cerebrovascular, and peripheral artery diseases. Antiplatelet therapy combinations as well as combination of antiplatelet and anticoagulant agents are examined in both the acute phase and long term, including management of individuals with sinus rhythm and those with atrial fibrillation. The difficulties in tailoring therapy according to the variable atherothrombotic risk in different individuals are emphasized, in addition to the varying risk within an individual secondary to DM duration, presence of complications and predisposition to bleeding events. This review provides the reader with an up-to-date guide for antithrombotic management of individuals with DM and highlights gaps in knowledge that represent areas for future research, aiming to improve clinical outcome in this high-risk population.

خرید پکیج و مشاهده آنلاین مقاله

ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB

Allan S Jaffe, Bertil Lindahl, Evangelos Giannitsis, Christian Mueller, Louise Cullen, Ola Hammarsten, Martin Mockel, Johannes Mair, Konstantin A Krychtiuk, Kurt Huber, Nicholas L Mills, Kristian Thygesen

doi : 10.1093/eurheartj/ehaa1079

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2260–2264

خرید پکیج و مشاهده آنلاین مقاله

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

Jurrien ten Berg, Dirk Sibbing, Bianca Rocca, Eric Van Belle, Bernard Chevalier, Jean-Philippe Collet, Dariusz Dudek, Martine Gilard, Diana A Gorog, Julia Grapsa, Erik Lerkevang Grove, Patrizio Lancellotti, Anna Sonia Petronio, Andrea Rubboli, Lucia Torracca, Gemma Vilahur, Adam Witkowski, Julinda Mehilli

doi : 10.1093/eurheartj/ehab196

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2265–2269

Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.

خرید پکیج و مشاهده آنلاین مقاله

C-reactive protein and clinical outcomes in patients with COVID-19

Nathaniel R Smilowitz, Dennis Kunichoff, Michael Garshick, Binita Shah, Michael Pillinger, Judith S Hochman, Jeffrey S Berger

doi : 10.1093/eurheartj/ehaa1103

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2270–2279

A systemic inflammatory response is observed in coronavirus disease 2019 (COVID-19). Elevated serum levels of C-reactive protein (CRP), a marker of systemic inflammation, are associated with severe disease in bacterial or viral infections. We aimed to explore associations between CRP concentration at initial hospital presentation and clinical outcomes in patients with COVID-19.

خرید پکیج و مشاهده آنلاین مقاله

C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?

Mark B Pepys

doi : 10.1093/eurheartj/ehab169

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2280–2283

خرید پکیج و مشاهده آنلاین مقاله

Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial

Ekkehard Grünig, Alison MacKenzie, Andrew J Peacock, Christina A Eichstaedt, Nicola Benjamin, Robert Nechwatal, Silvia Ulrich, Stéphanie Saxer, Maurizio Bussotti, Marinella Sommaruga, Stefano Ghio, Lina Gumbiene, Egl? Palevi?i?t?, Elena Jurevi?ien?, Antonio Cittadini, Anna A Stanziola, Alberto M Marra, Gabor Kovacs, Horst Olschewski, Joan-Albert Barberà, Isabel Blanco, Martijn A Spruit, Frits M E Franssen, Anton Vonk Noordegraaf, Ab?lio Reis, M?rio Santos, Sofia Gonçalves Viamonte, Heleen Demeyer, Marion Delcroix, Eduardo Bossone, Martin Johnson

doi : 10.1093/eurheartj/ehaa696

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2284–2295

This prospective, randomized, controlled, multicentre study aimed to evaluate efficacy and safety of exercise training in patients with pulmonary arterial (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

خرید پکیج و مشاهده آنلاین مقاله

Proof that exercise works, now it’s time for optimizing delivery to our patients with pulmonary hypertension

André La Gerche

doi : 10.1093/eurheartj/ehaa780

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2296–2298

خرید پکیج و مشاهده آنلاین مقاله

Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis

Ella Grilz, Florian Posch, Stephan Nopp, Oliver K?nigsbrügge, Irene M Lang, Peter Klimek, Stefan Thurner, Ingrid Pabinger, Cihan Ay

doi : 10.1093/eurheartj/ehab171

European Heart Journal, Volume 42, Issue 23, 14 June 2021, Pages 2299–2307

An interrelation between cancer and thrombosis is known, but population-based studies on the risk of both arterial thromboembolism (ATE) and venous thromboembolism (VTE) have not been performed.

خرید پکیج و مشاهده آنلاین مقاله